Promising results from gene therapy trial in advanced PD reported

Specialists have reported promising initial findings from a trial of VY‐AADC01, an adeno-associated virus serotype 2 (AAV2) gene therapy encoding human aromatic L‐amino acid decarboxylase (AADC), in patients with advanced Parkinson’s disease.

Dr Chad Christine from the University of California San Francisco, USA, presented preliminary 3-year data from the PD-1101 trial of the gene therapy.

In the trial, 15 patients were given bilateral, intraoperative MRI-guided putaminal infusions of the gene therapy at three doses (5 patients in each dose cohort). Dr Christine reported that:

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.